Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
Lilly calls time on IDH1/2 inhibition
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
